欢迎来到天天文库
浏览记录
ID:55596628
大小:315.92 KB
页数:5页
时间:2020-05-20
《索拉菲尼与卡培他滨对晚期肝细胞癌患者化疗的对比分析.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、第41卷第1期JournalofL兰an州zIh大ou学U学niv报ers(it医y(M学e版dic)alSciences)Vo1.41NO.12015年2月Feb.2015文章编号:1000—2812(2015)01—0050—05索拉菲尼与卡培他滨对晚期肝细胞癌患者化疗的对比分析刘小红,赵磊,吕西,曾祥挺,贺东强,宋爱琳兰州大学第二医院普外科,甘肃兰州730030摘要:目的比较索拉菲尼与卡培他滨在治疗晚期肝细胞癌中的安全性与有效性。方法回顾性分析2009年1月一2011年1月收治并确诊的晚期不能手术的肝细胞癌患者36例,口服索拉菲尼组18例,El服卡培他
2、滨组18例,观察2种化疗方案对晚期肝细胞癌患者短期疗效、远期疗效以及毒副反应。结果短期疗效分析,索拉菲尼组和卡培他滨组的疾病控制率之间差异无统计学意义。远期疗效分析,索拉菲尼的无进展生存期和总生存期分别为8.265个月和9.539个月,明显高于卡培他滨组的无进展生存期(5.367个月)和总生存期(6.188个月),P<0.05,差异有统计学意义。索拉菲尼组的血小板减少以及肝功能异常出现率明显低于卡培他滨组(P3、尼。关键词i索拉菲尼;卡培他滨;晚期肝细胞癌;化疗中图分类号:R735.7文献标识码:Adoi:10.13885d.issn.1000—2812.2015.O1.009DifferencesanalysisofsorafenibandcapecitabineforadvancedhepatocarcinomaLiuXiao—hong,ZhaoLei,LtiXi,ZengXiang—ting,HeDong—qiang,SongAi—linDepartmentofGeneralSurgery,SecondHospitalofLanzhouUniversity,L4、anzhou730030,ChinaAbstract:ObjectiveExplorethedifferenceofsafetyandeffectbetweensorafenibandcapecitabineinad—vancedhepatocarcinoma.MethodsRetrospectivelyanalyzetheadvancedinoperablehepatocarcinomapa-tientsfromJanuary2009toJanuary2011inourhospitalthatinclude18patientswithoralsorafen5、iborcapecitabineandanalyzethediferenceofshort—termeffect,long—termefectandtoxicitybetweentwogroups.ResultsThediseasecontrolrateofsorafenibwashigherthaneapecitabinegroups,withoutstatisticalsignificance;long—termeffect:theprogressionfreesurvivalandoverallsurvivalofsorafenibrespective6、lywere8.265monthsand9.539monthswhichwerehigherthancapecitabinegroupsf5.367monthsand6.188months),P<0.05,thediferencehasstatisticallysignificant;toxicity:therateofthrombocytopeniaanddys—functionofliverofsorafenibweresignificantlowerthanthoseofcapecitabinerP<0.0s).ConclusionSorafenibh7、asabetterefectandlowertoxicitycomparedcapecitabineforadvancedhepatocarcinoma,SOitcanbeusedasaneffectivechoiceinclinic.Keywords:sorafenib;capecitabine;advancedhepatocarcinoma;chemotherapy收稿日期:2014—07—01基金项目:甘肃省自然科学基金项目(1107RJZA186)作者简介:刘小红(1976一),男,甘肃兰州人,主治医师,研究方向为肝胆外科,e-mail:onlyha8、wk@163.com;宋爱琳(1966-),女,甘肃
3、尼。关键词i索拉菲尼;卡培他滨;晚期肝细胞癌;化疗中图分类号:R735.7文献标识码:Adoi:10.13885d.issn.1000—2812.2015.O1.009DifferencesanalysisofsorafenibandcapecitabineforadvancedhepatocarcinomaLiuXiao—hong,ZhaoLei,LtiXi,ZengXiang—ting,HeDong—qiang,SongAi—linDepartmentofGeneralSurgery,SecondHospitalofLanzhouUniversity,L
4、anzhou730030,ChinaAbstract:ObjectiveExplorethedifferenceofsafetyandeffectbetweensorafenibandcapecitabineinad—vancedhepatocarcinoma.MethodsRetrospectivelyanalyzetheadvancedinoperablehepatocarcinomapa-tientsfromJanuary2009toJanuary2011inourhospitalthatinclude18patientswithoralsorafen
5、iborcapecitabineandanalyzethediferenceofshort—termeffect,long—termefectandtoxicitybetweentwogroups.ResultsThediseasecontrolrateofsorafenibwashigherthaneapecitabinegroups,withoutstatisticalsignificance;long—termeffect:theprogressionfreesurvivalandoverallsurvivalofsorafenibrespective
6、lywere8.265monthsand9.539monthswhichwerehigherthancapecitabinegroupsf5.367monthsand6.188months),P<0.05,thediferencehasstatisticallysignificant;toxicity:therateofthrombocytopeniaanddys—functionofliverofsorafenibweresignificantlowerthanthoseofcapecitabinerP<0.0s).ConclusionSorafenibh
7、asabetterefectandlowertoxicitycomparedcapecitabineforadvancedhepatocarcinoma,SOitcanbeusedasaneffectivechoiceinclinic.Keywords:sorafenib;capecitabine;advancedhepatocarcinoma;chemotherapy收稿日期:2014—07—01基金项目:甘肃省自然科学基金项目(1107RJZA186)作者简介:刘小红(1976一),男,甘肃兰州人,主治医师,研究方向为肝胆外科,e-mail:onlyha
8、wk@163.com;宋爱琳(1966-),女,甘肃
此文档下载收益归作者所有